Mural Oncology plc (MURA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
10 Earlsfort Terrace
Dublin, D02 T380
Ireland
Phone
353 1 905 8020
Sector
Healthcare
Industry
Biotechnology
Employees
116
First IPO Date
November 16, 2023
| Name | Title | Pay | Year Born |
| Caroline J. Loew | President, Chief Executive Officer & Director | 1.01M | 1971 |
| Adam D. Cutler | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 735,250 | 1974 |
| Vicki L. Goodman | Chief Medical Officer | 987,250 | 1970 |
| Justin Levine | Head of Human Resources & Vice President of Human Resources | 0 | N/A |
| Maiken Keson-Brookes | Chief Legal Officer | 0 | 1973 |
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.